ATE489108T1 - Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie - Google Patents

Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Info

Publication number
ATE489108T1
ATE489108T1 AT99956525T AT99956525T ATE489108T1 AT E489108 T1 ATE489108 T1 AT E489108T1 AT 99956525 T AT99956525 T AT 99956525T AT 99956525 T AT99956525 T AT 99956525T AT E489108 T1 ATE489108 T1 AT E489108T1
Authority
AT
Austria
Prior art keywords
tumor
flt4
vegfr
imaging
target
Prior art date
Application number
AT99956525T
Other languages
English (en)
Inventor
Kari Alitalo
Arja Kaipainen
Reija Valltola
Lotta Jussila
Original Assignee
Vegenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/169,079 external-priority patent/US6824777B1/en
Application filed by Vegenics Ltd filed Critical Vegenics Ltd
Application granted granted Critical
Publication of ATE489108T1 publication Critical patent/ATE489108T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
AT99956525T 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie ATE489108T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/169,079 US6824777B1 (en) 1992-10-09 1998-10-09 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en) 1998-10-09 1999-10-08 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (1)

Publication Number Publication Date
ATE489108T1 true ATE489108T1 (de) 2010-12-15

Family

ID=22614189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956525T ATE489108T1 (de) 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Country Status (13)

Country Link
US (4) US8444957B2 (de)
EP (1) EP1119371B1 (de)
JP (5) JP4841724B2 (de)
CN (1) CN100340291C (de)
AT (1) ATE489108T1 (de)
AU (2) AU774266B2 (de)
CA (1) CA2345276C (de)
DE (1) DE69942981D1 (de)
DK (1) DK1119371T3 (de)
ES (1) ES2357406T3 (de)
NO (1) NO20011759L (de)
NZ (2) NZ511408A (de)
WO (1) WO2000021560A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
EP1382679A3 (de) 1995-09-08 2004-11-10 Genentech, Inc. Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CN100340291C (zh) * 1998-10-09 2007-10-03 路德维格癌症研究院 F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (de) * 1999-04-13 2005-07-13 Medarex, Inc. Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
DE60131146T2 (de) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2005049852A2 (en) * 2003-11-17 2005-06-02 University Of Florida Methods and compositions for inducing apoptosis
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
US8305579B2 (en) 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US9677125B2 (en) 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
EP2538965B1 (de) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2911681A1 (de) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
EP0171407B1 (de) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Verbesserungen an wachstumsfaktoren
AU622105B2 (en) 1987-03-11 1992-04-02 Austin Research Institute, The Immunoglobulin conjugates
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
JPH04505260A (ja) 1989-05-22 1992-09-17 ザイモジェネティクス，インコーポレイティド ＰＤＧＦα―受容体
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
JPH06507543A (ja) 1991-01-31 1994-09-01 コア　セラピューティクス，インコーポレイティド ヒト血小板由来成長因子レセプターポリペプチドの細胞外領域ドメイン
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
DK0536350T3 (da) 1991-02-22 2002-09-02 American Cyanamid Co Identifikation af et nyt humant receptor-tyrosinkinase-gen
US5231001A (en) 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
CA2127540A1 (en) 1992-01-09 1993-07-22 Juha Partanen Tie, a novel endothelial cell receptor tyrosine kinase
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU3482493A (en) 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
WO1995024473A1 (en) 1994-03-08 1995-09-14 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
DK0807124T3 (da) * 1994-06-09 2006-08-28 Licentia Oy Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
EP1382679A3 (de) 1995-09-08 2004-11-10 Genentech, Inc. Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP)
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
NZ505011A (en) 1997-12-24 2004-12-24 Ludwig Inst Cancer Res Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
CN100340291C (zh) * 1998-10-09 2007-10-03 路德维格癌症研究院 F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶
KR101681886B1 (ko) 2015-04-06 2016-12-12 서울대학교산학협력단 지르코니아 결합능을 가지는 펩타이드

Also Published As

Publication number Publication date
JP2012019790A (ja) 2012-02-02
NZ511408A (en) 2004-04-30
WO2000021560A9 (en) 2000-09-21
NO20011759D0 (no) 2001-04-06
EP1119371B1 (de) 2010-11-24
ES2357406T3 (es) 2011-04-26
NO20011759L (no) 2001-06-11
DK1119371T3 (da) 2011-03-07
CN1329504A (zh) 2002-01-02
CA2345276C (en) 2011-03-29
AU2004208675B2 (en) 2006-03-02
NZ529063A (en) 2005-07-29
AU1312100A (en) 2000-05-01
AU2004208675A1 (en) 2004-09-30
DE69942981D1 (de) 2011-01-05
US20160184405A1 (en) 2016-06-30
AU774266B2 (en) 2004-06-24
US20140072511A1 (en) 2014-03-13
CN100340291C (zh) 2007-10-03
JP2013209382A (ja) 2013-10-10
US20100278736A1 (en) 2010-11-04
JP5642637B2 (ja) 2014-12-17
EP1119371A1 (de) 2001-08-01
JP5784310B2 (ja) 2015-09-24
US20150158928A1 (en) 2015-06-11
JP4841724B2 (ja) 2011-12-21
US8444957B2 (en) 2013-05-21
JP2002527404A (ja) 2002-08-27
CA2345276A1 (en) 2000-04-20
JP2015157829A (ja) 2015-09-03
JP2011121957A (ja) 2011-06-23
WO2000021560A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
ATE489108T1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
NO20033285D0 (no) FLT4(VEGFR-3) som et mål for tumoravbildning og anti-tumor terapi
DE69634437D1 (de) Vegf-c-rezeptorligand
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
CY1112101T1 (el) Νευροτροφικοι παραγοντες
CY1107339T1 (el) Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
WO1999033870A3 (en) Human regulatory proteins
GB9811260D0 (en) Novel compounds
CY1105820T1 (el) Basb027 πρωτεϊνες και γονιδια απο moraxella catarrhalis, αντιγονα, αντισωματα και χρησεις
EP0821060A3 (de) E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
GB9820003D0 (en) Novel compounds
WO2000023589A3 (en) Proliferation and apoptosis related proteins
GB9809683D0 (en) Novel compounds
GB9810285D0 (en) Novel compounds
GB9812163D0 (en) Novel compounds
TR200102745T2 (tr) Yeni bileşikler
GB9812440D0 (en) Novel compounds
GB9918208D0 (en) Novel compounds
WO2003016479A3 (en) Excitatory glycine receptors and methods
AU2002360392A8 (en) New gene expressed in prostate cancer and methods of use
GB0025170D0 (en) Novel compounds
GB9918003D0 (en) Novel compounds
GB9918302D0 (en) Novel compounds
ATE293693T1 (de) Moraxella catarrhalis antigen basb117
BR1100558A (pt) famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1119371

Country of ref document: EP